RobertSomerMD

Oncology • Voorhees, NJ

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Genitourinary Oncology

Head, Division of Hematology and Oncology, MD Anderson Cancer Center at Cooper Director, Clinical Trials Program, MD Anderson Cancer Center at Cooper Professor of Medicine, Cooper Medical School of Rowan University

Join to view full profile

Dr. Somer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Somer's full profile

Already have an account?

Office
900 Centennial Blvd Ste M
Suite M
Voorhees, NJ 08043
Phone+1 856-325-6750

Fax+1 856-325-6777

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Pennsylvania Health SystemResidency, Internal Medicine, 1997 - 2000
Stony Brook University Health Sciences Center School of MedicineClass of 1997

Certifications & Licensure

PA State Medical License 1998 - 2024
NJ State Medical License 2003 - 2023
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

515 citations
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Dirix, István Takács, Guy Jerusalem, Petros Nikolinakos, Hendrik Tobias Arkenau
Breast Cancer Research and Treatment. 2018-10-23
14 citations
Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer.
Chelsea K. Osterman, Dilip Sankar Babu, Daniel M. Geynisman, Bianca Lewis, Robert A. Somer
The Oncologist. 2019-05-01
124 citations
Randomized Phase I Trial of Recombinant Human Keratinocyte Growth Factor Plus Chemotherapy: Potential Role as Mucosal Protectant
Neal J. Meropol, Robert A. Somer, John Gutheil, Robert J. Pelley, Manuel R. Modiano
Journal of Clinical Oncology. 2003-04-15

Press Mentions

N.J.’s 2021 Top Cancer Doctors Lead Charge to Help Patients Thrive and Survive After PandemicJune 17th, 2021